EagleClaw Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.1M | Sell |
71,774
-460
| -0.6% | -$99K | 2.42% | 7 |
|
|
2026
Q1 | $15.7M | Buy |
72,234
+740
| +1% | +$164K | 2.2% | 7 |
|
|
2025
Q4 | $16.3M | Sell |
71,494
-630
| -0.9% | -$144K | 2.36% | 9 |
|
|
2025
Q3 | $16.7M | Sell |
72,124
-1,788
| -2% | -$364K | 2.34% | 9 |
|
|
2025
Q2 | $13.7M | Sell |
73,912
-15
| -0% | -$2.79K | 2.05% | 12 |
|
|
2025
Q1 | $15.5M | Buy |
73,927
+4,102
| +6% | +$797K | 2.44% | 6 |
|
|
2024
Q4 | $12.4M | Buy |
69,825
+1,948
| +3% | +$358K | 1.97% | 11 |
|
|
2024
Q3 | $13.4M | Sell |
67,877
-1,138
| -2% | -$212K | 2.24% | 8 |
|
|
2024
Q2 | $11.8M | Sell |
69,015
-575
| -0.8% | -$95.2K | 2.13% | 9 |
|
|
2024
Q1 | $12.7M | Sell |
69,590
-400
| -0.6% | -$68.9K | 2.3% | 8 |
|
|
2023
Q4 | $10.8M | Sell |
69,990
-50
| -0.1% | -$7.29K | 2.26% | 8 |
|
|
2023
Q3 | $10.4M | Buy |
70,040
+1,060
| +2% | +$156K | 2.37% | 7 |
|
|
2023
Q2 | $9.29M | Buy |
68,980
+740
| +1% | +$109K | 2.14% | 10 |
|
|
2023
Q1 | $10.9M | Sell |
68,240
-260
| -0.4% | -$39.8K | 2.56% | 5 |
|
|
2022
Q4 | $11.1M | Sell |
68,500
-65
| -0.1% | -$9.97K | 2.68% | 5 |
|
|
2022
Q3 | $9.2M | Buy |
68,565
+35
| +0.1% | +$5.02K | 2.57% | 5 |
|
|
2022
Q2 | $10.5M | Sell |
68,530
-925
| -1% | -$141K | 2.85% | 5 |
|
|
2022
Q1 | $11.3M | Sell |
69,455
-1,718
| -2% | -$250K | 2.59% | 6 |
|
|
2021
Q4 | $9.64M | Buy |
71,173
+900
| +1% | +$106K | 2.11% | 9 |
|
|
2021
Q3 | $7.58M | Buy |
70,273
+2,524
| +4% | +$288K | 1.95% | 11 |
|
|
2021
Q2 | $7.63M | Buy |
67,749
+3,150
| +5% | +$355K | 1.97% | 9 |
|
|
2021
Q1 | $6.98M | Buy |
64,599
+5,275
| +9% | +$564K | 2.01% | 9 |
|
|
2020
Q4 | $6.36M | Buy |
59,324
+4,375
| +8% | +$420K | 2.02% | 9 |
|
|
2020
Q3 | $4.81M | Buy |
54,949
+2,950
| +6% | +$278K | 1.69% | 16 |
|
|
2020
Q2 | $5.11M | Sell |
51,999
-117
| -0.2% | -$10.3K | 1.98% | 13 |
|
|
2020
Q1 | $3.96M | Buy |
52,116
+225
| +0.4% | +$19.2K | 1.87% | 14 |
|
|
2019
Q4 | $4.59M | Sell |
51,891
-75
| -0.1% | -$6.23K | 1.68% | 14 |
|
|
2019
Q3 | $3.94M | Buy |
51,966
+632
| +1% | +$43.3K | 1.6% | 16 |
|
|
2019
Q2 | $3.74M | Hold |
51,334
| – | – | 1.63% | 16 |
|
|
2019
Q1 | $4.13M | Sell |
51,334
-550
| -1% | -$45K | 1.88% | 12 |
|
|
2018
Q4 | $4.79M | Buy |
51,884
+293
| +0.6% | +$25.8K | 2.51% | 8 |
|
|
2018
Q3 | $4.88M | Sell |
51,591
-200
| -0.4% | -$19K | 2.14% | 9 |
|
|
2018
Q2 | $4.8M | Sell |
51,791
-250
| -0.5% | -$24.4K | 2.33% | 8 |
|
|
2018
Q1 | $4.93M | Sell |
52,041
-725
| -1% | -$79.6K | 2.5% | 8 |
|
|
2017
Q4 | $5.11M | Buy |
52,766
+475
| +0.9% | +$44.8K | 2.58% | 7 |
|
|
2017
Q3 | $4.64M | Sell |
52,291
-1,575
| -3% | -$120K | 2.63% | 7 |
|
|
2017
Q2 | $3.91M | Sell |
53,866
-475
| -0.9% | -$31.9K | 2.29% | 9 |
|
|
2017
Q1 | $3.54M | Sell |
54,341
-1,250
| -2% | -$78.6K | 2.13% | 8 |
|
|
2016
Q4 | $3.49M | Sell |
55,591
-50
| -0.1% | -$3.05K | 2.2% | 9 |
|
|
2016
Q3 | $3.51M | Buy |
55,641
+523
| +0.9% | +$33.9K | 2.24% | 7 |
|
|
2016
Q2 | $3.42M | Buy |
55,118
+1,400
| +3% | +$85.3K | 2.27% | 8 |
|
|
2016
Q1 | $3.07M | Sell |
53,718
-250
| -0.5% | -$13.9K | 2.08% | 10 |
|
|
2015
Q4 | $3.21M | Sell |
53,968
-600
| -1% | -$34.6K | 2.13% | 9 |
|
|
2015
Q3 | $2.97M | Sell |
54,568
-600
| -1% | -$39.1K | 2.09% | 9 |
|
|
2015
Q2 | $3.71M | Sell |
55,168
-100
| -0.2% | -$6.53K | 2.37% | 5 |
|
|
2015
Q1 | $3.24M | Buy |
55,268
+325
| +0.6% | +$19.6K | 2.1% | 8 |
|
|
2014
Q4 | $3.6M | Sell |
54,943
-100
| -0.2% | -$6.3K | 2.37% | 5 |
|
|
2014
Q3 | $3.18M | Buy |
55,043
+1,300
| +2% | +$72.2K | 2.16% | 6 |
|
|
2014
Q2 | $3.04M | Buy |
53,743
+3,750
| +8% | +$197K | 2.06% | 9 |
|
|
2014
Q1 | $2.57M | Buy |
+49,993
| New | +$2.53M | 1.86% | 14 |
|
Other funds holding ABBV
EagleClaw Capital Management's ABBV Position: Q2 2026 in Review
EagleClaw Capital Management reduced its AbbVie (ABBV) stake by 0.64% in Q2 2026, selling an estimated $99K and leaving 71,774 shares worth $18.1M. The position accounts for 2.42% of the portfolio, ranked #7.
EagleClaw Capital Management first reported a position in ABBV in Q1 2014 and has held it in 50 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- EagleClaw Capital Management held 71,774 shares of AbbVie worth $18.1M as of Q2 2026.
- EagleClaw Capital Management sold 460 AbbVie shares in Q2 2026, an estimated $99K.
- AbbVie made up 2.42% of EagleClaw Capital Management's portfolio in Q2 2026, its #7 holding.
- EagleClaw Capital Management first reported a position in AbbVie in Q1 2014 and has held it in 50 quarters since.
- 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.